VioQuest Pharmaceuticals, Inc. To Present At The 17th Annual Wall Street Analyst Forum
BASKING RIDGE, N.J., Sept. 28 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals, Inc. , a New Jersey-based biopharmaceutical company, announced today that Daniel Greenleaf, president and chief executive officer, will present at the Wall Street Analyst Forum on Thursday, September 28, 2006 at 12:40 pm EDT at The Princeton Club in New York City. Mr. Greenleaf will provide an overview of the Company and an update on its clinical development programs, including the two targeted cancer agents, VQD-001, currently in Phase I/IIa clinical trials for solid tumors, and VQD- 002 in clinical trials for leukemia and for solid tumors. Mr. Greenleaf will also discuss the upcoming NDA filing for Leishmaniasis for VQD-001.
The Wall Street Analyst Forum has been a sponsor of four annual analyst conferences in New York, Boston and London since 1988 involving NYSE/NASDAQ/AMEX corporations.
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. A pioneer in personalized therapeutics, VioQuest has two targeted oncology compounds in clinical trials: VQD-001, an inhibitor of specific protein tyrosine phosphatases, which has shown compelling preclinical activity in both renal and melanoma cancers, and VQD-002, a specific inhibitor of phosphorylated Akt, which has also shown compelling preclinical activity in abnormal levels in breast, ovarian, colorectal, pancreatic, and liquid cancers.
VioQuest's subsidiary Chiral Quest, a leader in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug.
This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the FDA will approve VioQuest's planned NDA submission relating to VQD-001 for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize VQD-001 for the treatment of leishmaniasis or any other indication. Other risks and uncertainties include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including VQD-001 and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2005. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Contact: VioQuest Pharmaceuticals, Inc.: Daniel Greenleaf Brian Lenz Chief Executive Officer Chief Financial Officer 908-766-4400 908-766-4400 Noonan Russo: Sharon Weinstein Benjamin Carmichael Investor Relations Media 212-845-4271 212-845-4242VioQuest Pharmaceuticals, Inc.
CONTACT: VioQuest Pharmaceuticals, Inc. - Daniel Greenleaf, ChiefExecutive Officer, +1-908-766-4400, or Brian Lenz, Chief Financial Officer,+1-908-766-4400, or Noonan Russo - Investor, Sharon Weinstein, +1-212-845-4271, or Media, Benjamin Carmichael, 212-845-4242